Reply to H. McLeod et al

Affiliations

¹ Chana Weinstock, MD; Laura L. Fernandes, PhD; Marc Theoret, MD; Shenghui Tang, PhD; Rajeshwari Sridhara, PhD; Julia A. Beaver, MD; and Richard Pazdur, MD, US Food and Drug Administration, Silver Spring, MD.

Comment

Chana Weinstock et al. J Clin Oncol. 2020.

. 2020 Jan 1;38(1):106.

doi: 10.1200/JCO.19.02429. Epub 2019 Nov 1.

¹ Chana Weinstock, MD; Laura L. Fernandes, PhD; Marc Theoret, MD; Shenghui Tang, PhD; Rajeshwari Sridhara, PhD; Julia A. Beaver, MD; and Richard Pazdur, MD, US Food and Drug Administration, Silver Spring, MD.

No abstract available

Comment on

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody.
Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, Ning YM, Singh H, Suzman D, Xu J, Goldberg KB, Sridhara R, Ibrahim A, Theoret M, Beaver JA, Pazdur R. Maher VE, et al. J Clin Oncol. 2019 Oct 20;37(30):2730-2737. doi: 10.1200/JCO.19.00318. Epub 2019 May 22. J Clin Oncol. 2019. PMID: 31116675
Assessment of Adverse Events and Their Ability to Discriminate Response to Anti-PD-1/PD-L1 Antibody Immunotherapy.
McLeod HL, Mariam A, Schveder KA, Rotroff DM. McLeod HL, et al. J Clin Oncol. 2020 Jan 1;38(1):103-104. doi: 10.1200/JCO.19.01712. Epub 2019 Nov 1. J Clin Oncol. 2020. PMID: 31675248 No abstract available.